Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells

Published:2013-11 Issue:10 Volume:24 Page:1039-1046
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Chen Xi,Zhou Jian-Ya,Zhao Jing,Chen Jun-Jun,Ma Shan-Ni,Zhou Jian-Ying

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference8 articles.

1. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.;Dienstmann;Mol Oncol,2012

2. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.;Mitsudomi;Cancer Sci,2007

3. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.;Zillhardt;Neoplasia,2010

4. Role of c-Met in cancer: emphasis on lung cancer.;Salgia;Semin Oncol,2009

5. Targeting the HGFMet signaling pathway in cancer therapy.;Cecchi;Expert Opin Ther Targets,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

3. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer;Medicinal Research Reviews;2020-06-29

4. Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine;Medicine;2018-11

5. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?;Cancer Treatment Reviews;2017-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3